Immunoassays are an essential analytical tool used throughout the development and manufacturing of cell and gene therapies to evaluate viral vector titers and process impurities. The two most commonly used vehicles for delivery of gene therapies into mammalian cells are adeno-associated virus (AAV) and lentiviral vectors, and consequently AAV titer and lentiviral titer ELISA assays are commonly developed for this purpose. However, lengthy assay development and sample analysis times using traditional ELISA methods often cause delays in program schedules.
The use of robust immunoassay platforms for analysis in gene therapy development can streamline production. The automated Gyrolab® platform significantly reduces time to results, sample volume, and improves data quality for AAV- and lentivirus-based gene therapy immunoassays during development, and is ideally suited for compressed cell and gene therapy development timelines.
Gyrolab Systems are reliable and precise walk-away automated immunoassay systems that give you and your team the agility to develop immunoassays more quickly with minimal hands-on time, accelerating every phase of biotherapeutic product development.
The systems are a powerful tool for increasing productivity, generating reproducible data, and making data-driven decisions faster.
Eliminate workflow bottlenecks by letting our highly experienced scientists optimize your assays for the Gyrolab® platform.
Accelerate development of commonly used immunoassays, with ready-to-use and robust Gyrolab assay protocols.
Ask an expert how Gyrolab platform can help maximize immunoassay speed and quality in cell and gene therapy development.